Abstract
Background
Neuroendocrine tumors (NETs) have a propensity to metastasize to the liver, often resulting in massive tumor burden and hepatic dysfunction. While transarterial chemoembolization (TACE) is effective in treating patients with NET metastatic to the liver, there are limited data on its utility and benefit in patients with large hepatic involvement. The aim of our study was to determine the clinical benefit and complication rate of TACE in patients with massive hepatic tumor burden.
Methods
Medical records were reviewed in patients with grade 1 or 2 NETs with hepatic metastasis at our institution from January 2000 to September 2014 who underwent TACE. Of 201 total patients, 68 had massive hepatic tumor burden involving >75 % of liver parenchyma.
Results
Carcinoid syndrome was present in 40 (59 %) patients, and 57 (84 %) of the 68 patients were symptomatic from their disease. Complications beyond post-TACE syndrome occurred in 21.7 % of patients, with the most common complication being cardiac arrhythmias. The 30-day mortality rate was 7 %. Biochemical response was observed in 78 % of patients, while symptomatic relief and radiographic response was achieved in 85 and 82 % of patients, respectively. Median overall survival following TACE was 28 months, with 1-, 2-, and 5-year overall survival of 76, 54, and 26 %, respectively.
Conclusions
In spite of massive tumor burden, clinical and biochemical improvements were seen in the majority of patients. Morbidity was acceptable and reversible but with a fairly high mortality rate of 7 %. TACE should still be considered in selective patients with massive hepatic tumor burden from metastatic NET for symptom control and palliation.
Similar content being viewed by others
References
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Et Al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (gep-nets): results from the national cancer registry of spain (rgetne). Ann Oncol. 2010;21(9):1794–1803.
Lawrence B, Gustafsson Bi, Chan A, Svejda B, Kidd M, Modlin Im. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18.
Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040–3044.
Modlin Im, Champaneria Mc, Chan Ak, Kidd M. A Three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol. 2007;102(7):1464–1473.
Yao Jc, Hassan M, Phan A, Et Al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J Clin Oncol. 2008;26(18):3063–3072.
Rindi G, D’adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol. 2007;18(3):145–149.
Gupta S, Yao Jc, Ahrar K, Et Al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the m.d. anderson experience. Cancer J. 2003;9(4):261–267.
Chamberlain Rs, Canes D, Brown Kt, Et Al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–445.
Godwin Jd Ii. Carcinoid Tumors. An analysis of 2,837 Cases. Cancer. 1975;36(2):560–569.
Modlin Im, Lye Kd, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959.
Touzios JG, Kiely JM, Pitt SC, Et Al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241(5):776–783; Discussion 783–775.
Kress O, Wagner Hj, Wied M, Klose Kj, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single-center analysis. Digestion. 2003;68(2–3):94–101.
Chen H, Hardacre Jm, Uzar A, Cameron Jl, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187(1):88–92, Discussion 92–83.
Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol. 2013;30(1):28-38.
Liu Dm, Kennedy A, Turner D, Et Al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol. 2009;32(2):200–215.
Madoff DC, Gupta S, Ahrar K, Murthy R, Yao Jc. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006;17(8):1235–1249, Quiz 1250.
Osborne Da, Zervos Ee, Strosberg J, Et Al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–581.
Musunuru S, Chen H, Rajpal S, Et Al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141(10):1000–1004, Discussion 1005.
Yao Ka, Talamonti MS, Nemcek A, Et Al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130(4):677–682, Discussion 682–675.
Modlin Im, Latich I, Kidd M, Zikusoka M, Eick G. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4(5):526–547.
Khasraw M, Gill A, Harrington T, Pavlakis N, Modlin I. Management of advanced neuroendocrine tumors with hepatic metastasis. J Clin Gastroenterol. 2009;43(9):838–847.
Yamada R, Nakatsuka H, Nakamura K, Et Al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26(2):81–96.
Arrese D, Mcnally Me, Chokshi R, Et Al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol. 2013;20(4):1114–1120.
Gupta S, Johnson Mm, Murthy R, Et Al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590–1602.
Bloomston M, Al-Saif O, Klemanski D, Et Al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11(3):264–271.
Roche A, Girish Bv, De Baere T, Et Al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology. 2004;51(60):1751–1756.
Frilling A, Li J, Malamutmann E, Schmid Kw, Bockisch A, Broelsch Ce. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175–184.
Frilling A, Sotiropoulos Gc, Li J, Kornasiewicz O, Plockinger U. Multimodal management of neuroendocrine liver metastases. Hpb 2010;12(6):361–379.
Kamat Pp, Gupta S, Ensor Je, Et Al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol. 2008;31(2):299–307.
Desai Dc, O’dorisio Tm, Schirmer Wj, Et Al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96(3):113–117.
Ruutiainen At, Soulen Mc, Tuite Cm, Et Al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18(7):847–855.
Disclosure
Mio Kitano, Gail W. Davidson, Lawrence A. Shirley, Carl R. Schmidt, Gregory E. Guy, Hooman Khabiri, Joshua D. Dowell, Manisha H. Shah, and Mark Bloomston have no disclosures to declare.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kitano, M., Davidson, G.W., Shirley, L.A. et al. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?. Ann Surg Oncol 23, 4008–4015 (2016). https://doi.org/10.1245/s10434-016-5333-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5333-x